Tekla Life Sciences Investors
NYSE:HQLAsset Management
+$0.11 today
- Market cap
- $585.96M
- Beta
- 0.73
- P/E (TTM)
- 2.8
- EPS (TTM)
- $6.52
- Dividend yield
- 11.35%
Volume 0.12M
Average 0.11M
HQL Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Tekla Life Sciences InvestorsNYSE: HQL
Net Receivables · Q2 FY2026 · quarter ended Mar 2026
Net receivables falls 80.0% from a year ago
Net receivables stood at $1.28M at the end of Q2 FY2026, down 80.0% from a year earlier. Over 3 fiscal years it compounded at +22.2% a year.
Context
- Net receivables amounted to 0.2% of total assets at the end of Q2 FY2026, down 1.3 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -80.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 1.14M USD
- Year-over-year change
- +392.5%
- 4-year CAGR
- +65.9%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 1.14M | +392.5% |
| FY2024 | 2024-09-30 | 231.11K | -95.4% |
| FY2023 | 2023-09-30 | 5.04M | +709.1% |
| FY2022 | 2022-09-30 | 623.47K | +314.7% |
| FY2021 | 2021-09-30 | 150.34K | — |
Net Receivables vs competitors
How HQL compares with its peers on the latest reported figures
- HQL's Mar 2026 net receivables of $1.28M is the 8th highest of the 10 companies compared; the peer median is $6.82M.
- Its year-over-year change of -80.0% is the 8th highest of 10, against a peer median of -12.2%.
- Net receivables amounts to 0.2% of total assets for HQL, versus a peer median of 0.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $4.66B | +40752.9% | -34.2% | 0.4% | |
| Dec 2025 | $49.3M | -5.0% | +11.1% | 3.5% | |
| Mar 2026 | $23.42M | +176.7% | — | 1.4% | |
| Mar 2026 | $21.13M | -12.2% | +0.9% | 1.4% | |
| Mar 2026 | $6.82M | -28.5% | -0.6% | 0.5% | |
| Mar 2026 | $5.65M | +0.2% | +20.9% | 0.6% | |
| Dec 2025 | $2.37M | -25.3% | -5.8% | 0.6% | |
| Mar 2026 | $1.28M | -80.0% | +22.2% | 0.2% | |
| Mar 2026 | $48K | -99.9% | -86.8% | 0.0% | |
| Dec 2025 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding HQL) | $6.82M | -12.2% | -0.6% | 0.6% | |
Competitors are the stored peer set for HQL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 990 | 445 | 477 | 1 | 75.54K |
| Short-term Investments | 0 | 0 | 15.24M | 17.23M | 0 |
| Net Receivables | 150.34K | 623.47K | 5.04M | 231.11K | 1.14M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | (32.97K) | (25.18K) | 0 | 8.97K | 0 |
| Total Current Assets | 144.66K | 623.92K | 5.05M | 281.61K | 1.25M |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 534.01M | 414.08M | 397.53M | 460.3M | 505.7M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 534.01M | 414.7M | 402.57M | 13.9M | 514.13M |
| Total Non-current Assets | 534.01M | 414.08M | 397.53M | 474.2M | 514.13M |
| Total Assets | 534.19M | 414.73M | 402.6M | 460.58M | 515.38M |
| Account Payables | 150.34K | 5.1M | 0 | 1.79K | 720.9K |
| Short-term Debt | 10.04M | 11.09M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 5.09M | 0 | 0 | 0 |
| Other Current Liabilities | (8M) | (16.18M) | 0 | 50.81K | 0 |
| Total Current Liabilities | 10.75M | 5.1M | 0 | 888.61K | 720.9K |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 10.75M | 11.72M | 666.96K | 886.82K | 1.01M |
| Total Non-current Liabilities | 10.75M | 11.72M | 666.96K | 886.82K | 1.01M |
| Total Liabilities | 10.75M | 16.82M | 666.96K | 888.61K | 1.73M |
| Common Stock | 246.68K | 256.8K | 267.91K | 280.61K | 295.99K |
| Retained Earnings | 150.7M | 9.55M | (1.48M) | 44.13M | 77.6M |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 523.44M | 397.9M | 401.93M | 459.69M | 513.66M |
| Total Debt | 1.34M | 11.09M | 0 | 0 | 0 |
| Net Debt | 1.34M | 10.65K | (477) | (1) | (75.54K) |
Tekla Life Sciences Investors
NYSE:HQL
Intrinsic Alpha fair value
Locked
Current Price
$19.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.